Hamostaseologie 1985; 05(01): 1-7
DOI: 10.1055/s-0038-1655094
Originalarbeiten
Schattauer GmbH

Glykoproteine der Plättchenmembran

K. J. Clemetson
1   Theodor-Kocher-Institut, Universität Bern
,
E. F. Lüscher
1   Theodor-Kocher-Institut, Universität Bern
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

 

 
  • LITERATUR

  • 1 Caen J. P, Castaldi P. A, Ledere J. C, Inceman S, Larrieu M-J, Probst M, Bernard J. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann’s thrombasthenia (report of 15 patients). Amer. J. Med. 41: 4-26 1966;
  • 2 Nurden A. T, Caen J. P. An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. Brit. J. Haematol. 28: 253-260 1974;
  • 3 Phillips D. R, Jenkins C. S. P, Lüscher E. F, Larrieu M-J. Molecular differences of exposed surface proteins on thrombasthenie platelet plasma membranes. Nature 257: 599-600 1975;
  • 4 Phillips D. R, Poh-Agin P. Platelet membrane defects in Glanzmann’s thrombasthenia. J. Clin. Invest. 60: 535-545 1977;
  • 5 Kunicki T. J, Pidard D, Cazenave J-P, Nurden A. T, Caen J. P. Inheritance of the human platelet alio antigen P1A1 in Type I Glanzmann’s thrombasthenia. J. Clin. Invest. 67: 717-724 1981;
  • 6 Hagen I, Nurden A. T, Bjerrum O. J, Solum N. O, Caen J. P. Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann’s thrombasthenia and Bernard-Soulier syndrome. J. Clin. Invest. 65: 722-731 1980;
  • 7 Kunicki T. J, Pidard D, Rosa J. P, Nurden A. T. The formation of Ca2+-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood 58: 268-278 1981;
  • 8 Kunicki T. J, Aster R. H. Deletion of the platelet-specific alloantigen P1A1 from platelets in Glanzmann’s thrombasthenia. J. Clin. Invest. 61: 1225-1231 1978;
  • 9 Van Leuwen E. F, van dem Borne A. E. GK, von Riesz L. E, Nijenhuis L. E, Engelfriet C. P. Absence of platelet-specific alloantigens in Glanzmann’s thrombasthenia. Blood 57: 47-59 1981;
  • 10 Clemetson K. J, Capitanio A, Pareti F. I, McGregor J. L, Lüscher E. F. Additional platelet membrane glycoprotein abnormalities in Glanzmann’s thrombasthenia: A comparison with normals by high resolution two-dimensional polyacrylamide gel electrophoresis. Thromb. Res. 18: 797-806 1980;
  • 11 McGregor J. L, Clemetson K. J, James E, Capitanio A, Greenland T, Lüscher E. F, Dechavanne M. Glycoproteins of platelet membranes from Glanzmann’s thrombasthenia. A comparison with normal using carbohydrate-specific or protein-specific labelling techniques and high-resolution two-dimensional gel electrophoresis. Eur. J. Biochem. 116: 379-388 1981;
  • 12 Bennett J. S, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Invest. 64: 1393-1407 1979;
  • 13 Gogstad G. O, Brosstad F, Krutnes M-B, Hagen I, Solum N. O. Fibrinogenbinding properties of the human platelet glycoprotein IIb-IIIa complex: A study using crossed-immunoelectrophoresis. Blood 60: 663-671 1982;
  • 14 Mustard J. F, Kinlough-Rathbone R. L, Packham M. A, Perry D. W, Harfenist E. J, Pai K. R. M. Comparison of fibrinogen associated with normal and thrombasthenie platelets on exposure to ADP or chymotrypsin. Blood 54: 987-993 1979;
  • 15 McEver R. P, Bennett E. M, Martin M. N. Identification of two structurally and functionally distinct sites on human platelet membrane glycoprotein IIb-IIIa using monoclonal antibodies. J. Biol. Chem. 258: 5269-5275 1983;
  • 16 Plow E. F, Sronji A. H, Meyer D, Marguerie G, Ginsberg M. H. Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J. Biol. Chem. 259: 5388-5391 1984;
  • 17 Piéte G, Cherel G, Marguerie G, Meyer D. Inhibition of von Willebrand factorplatelet interaction by fibrinogen. Nature 308: 648-649 1984;
  • 18 Peerschke E. I, Grant R. A, Zucker M. B. Decreased association of 45Calcium with platelets unable to aggregate due to thrombasthenia or prolonged calcium deprivation. Brit. J. Haematol. 46: 247-256 1980;
  • 19 Gogstad G. O, Krutnes M-B, Solum N. O. Calcium-binding proteins from human platelets. A study using crossed immunoelectrophoresis and 45Ca2+ . Eur. J. Biochem. 133: 193-199 1983;
  • 20 Lightsey A. L, Plow E. F, McMillan R, Ginsberg M. H. Glanzmann’s thrombasthenia in the absence of GPIIb and III deficiency. Blood 88 (suppl.): 199a 1981;
  • 21 Nurden A. T, Rosa J-P, Boizard B, Didry D, Legrand C, Parquet A. Evidence that GPIIb-IIIa complexes are required for ADP-induced platelet aggregation. Studies on the platelets of a patient with a new type of Glanzmann’s thrombasthenia. Thrombos. Haemost. 50: 216 (abstr.) 1983;
  • 22 Jennings L. K, Phillips D. R. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-IIIa complex. J. Biol. Chem. 257: 10458-10466 1982;
  • 23 Leung L. L. K, Kinoshita T, Nachman R. L. Isolation, purification and partial characterization of platelet membrane glycoproteins lib and Ilia. J. Biol. Chem. 256: 1994-1997 1981;
  • 24 McEver R. P, Baenziger J. U, Majerus P. W. Isolation and structural characterization of the polypeptide subunits of membrane glycoprotein Ilb-IIIa from human platelets. Blood 59: 80-85 1982;
  • 25 Newman P. J, Kahn R. A. Purification of human platelet membrane glycoproteins lib and Ilia using high-performance liquid chromatography gel filtration. Anal. Biochem. 132: 215-218 1983;
  • 26 Shulman S, Wiesner R, Troll W, Karpatkin S. Reevaluation of the presence of the major antigen Ca2+ complex in Bernard-Soulier syndrome platelets. Thromb. Res. 30: 61-69 1983;
  • 27 Owen M. J, Kissonerghis A-M, Lodish H. F. Biosynthesis of HLA-A and HLAB antigens in vivo. J. Biol. Chem. 255: 9678-9684 1980;
  • 28 Gogstad G. O, Hagen I, Korsmo R, Solum N. O. Characterization of the proteins of isolated human platelet α-granules. Evidence for a separate α-granule pool of the glycoproteins IIIb and IIa. Biochem. Biophys. Acta. 670: 150-162 1981;
  • 29 Bernard J, Soulier J. P. Sur une nouvelle variété de dystrophie thrombocytaire hémorragipare congénitale. Sem. Hôp. Paris. 24: 3217-3223 1948;
  • 30 Weiss H. J, Tschopp T. B, Baumgartner H. R, Sussmann I. I, Johnson M. M, Egan J. J. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Amer. J. Med. 57: 920-925 1974;
  • 31 Howard M. A, Hutton R. A, Hardisty R. M. Hereditary giant platelet syndrome: A disorder of a new aspect of platelet function. Brit. Med. J. II: 586-588 1973;
  • 32 Jamieson G. A, Okumura T. Reduced thrombin binding and aggregation in Bernard-Soulier platelets. J. Clin. Invest. 61: 861-864 1978;
  • 33 White J. G, Barris S. M, Hasegawa D, Johnson M. Micropipette aspiration of human blood platelets. A defect in Bernard-Soulier’s syndrome. Blood 63: 1249-1252 1984;
  • 34 Grottum K. A, Solum N. O. Congenital thrombocytopenia with giant platelets, a defect in the platelet membrane. Brit. J. Haematol. 16: 277-290 1969;
  • 35 Nurden A. T, Caen J. P. Specific roles for platelet surface glycoproteins in platelet function. Nature 255: 720-722 1975;
  • 36 Jenkins C. S. P, Phillips D. R, Clemetson K. J, Meyer D, Larrieu M-J, Liischer E. F. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand’s disease. J. Clin. Invest. 57: 112-124 1976;
  • 37 Solum N. O, Hagen I, Gjemdal T. Platelet membrane glycoproteins and the interaction between bovine factor VIII related protein and human platelets. Thromb. Res. 38: 914-923 1977;
  • 38 Clemetson K. J, Naim N. Y, Lüscher E. F. Relationship between glycocalicin and glycoprotein Ib of human platelets. Proc. nat. Acad. Sci. (USA). 78: 2712-2716 1981;
  • 39 Clemetson K. J, McGregor J. L, James E, Dechavanne M, Liischer E. F. Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high resolution two-dimensional gel electrophoresis. J. Clin. Invest. 70: 304-311 1982;
  • 40 Berndt M. D, Gregory C, Chong B. M, Zola H, Castaldi P. Additional glycoprotein defects in Bernard-Soulier syndrome: Confirmation of genetic basis by parental analysis. Blood 62: 800-807 1983;
  • 41 Montgomery R. R, Kunicki T. J, Taves C, Pidard D, Corcoran M. Diagnosis of Bernard-Soulier syndrome and Glanzmann’s thrombasthenia with a monoclonal assay on whole blood. J. Clin. Invest. 71: 385-389 1983;
  • 42 Coller B. S, Peerschke E. J, Scudder L. E, Sullivan C. A. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: Additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 61: 99-110 1983;
  • 43 Okumura T, Jamieson G. A. Platelet glycoprotein: A single receptor for platelet aggregation induced by thrombin or ristocetin. Thromb. Res. 08: 701-706 1976;
  • 44 Fujimoto T, Ohara S, Hawiger J. Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/VWF on human platelets. J. Clin. Invest. 69: 1212-1222 1982;
  • 45 Ruggeri Z. M, Bader R, de Marco L. Glanzmann’s thrombasthenia: Deficient binding of von Willebrand factor to thrombin. Proc. nat. Acad. Sci. (USA) 79: 6038-6041 1982;
  • 46 Phillips D. R, Poh-Agin P. Platelet plasma membrane glycoproteins: Identification of a proteolytic substrate for thrombin. Biochem. Biophys. Res. Commun. 75: 940-947 1977;
  • 47 Tsuji T, Tsunekisa S, Watenabe Y, Yamamoto K, Tohyama H, Osawa T. The carbohydrate moiety of human platelet glycocalicin: The structure of the major Ser/Thr-linked chain. J. Biol. Chem. 258: 6335-6339 1983;
  • 48 Korrel S. A. M, Clemetson K. J, van Habeek H, Kamerling J. P, Sixma J. J, Vliegenthart J. F. G. Structural studies of the Olinked carbohydrate chains of human platelet glycocalicin. Eur. J. Biochem. 140: 571-576 1984;
  • 49 Bienz D. E, Clemetson K. J, Liischer E. F. Phosphorylation of platelet membrane glycoproteins. Experientia 40: 603 (abstr.) 1984;
  • 50 Berndt M. D, Phillips D. R. Purification and preliminary physicochemical characterization of human platelet membrane glycoprotein V. J. Biol. Chem. 256: 59-65 1981;
  • 51 Kunicki T. J, Aster R. H. Absence of the platelet receptor for drug dependent antibodies in the Bernard-Soulier syndrome. J. Clin. Invest. 62: 716-719 1978;
  • 52 Kunicki T. J, Russell N, Nurden A. T, Aster R. H, Caen J. P. Further studies of the human platelet receptor for quinineand quinidine-dependent antibodies. J. Immunol. 126: 398-402 1981;
  • 53 Bolin R. B, Okumura T, Jamieson G. A. New polymorphism of platelet membrane glycoproteins. Nature 269: 69-70 1977;
  • 54 Moroi M. Platelet glycoprotein Ib - its biochemical and physiological nature. Blood and Vessel. 15: 211-222 1984;
  • 55 Takahashi H. Type IIb and platelet-type von Willebrand’s disease. Heightened interaction between von Willebrand factor and platelets. Blood and Vessel. 15: 111-127 1984;
  • 56 Parkman R, Remold-O’Donnell E, Kenney D. M, Perrine S, Rosen F. S. Surface protein abnormalities in lymphocytes and platelets from patients with Wiskott-Aldrich syndrome. Lancet II: 1387 1981;
  • 57 McGregor J. L, Brochier J, Wild F, Follea G, Trzeciak M-C, James E, Dechavanne M, McGregor L, Clemetson K. J. Monoclonal antibodies against platelet membrane glycoproteins: Characterization and effect on platelet function. Eur. J. Biochem. 131: 427-436 1983;